問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Infectious Disease

更新時間：2023-09-19

王秉槐
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王秉槐

List

44Cases

2025-06-09 - 2029-11-26

Active
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    預充填式注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-04-01 - 2032-12-31

Active
A phase 3, multicenter, double-blind, placebo-controlled trial evaluating the efficacy and safety of olomorisabin in combination with standard-of-care immunotherapy in participants with resected or unresectable KRAS G12C-mutant non-small cell lung cancer – SUNRAY-02

  • Condition/Disease

    Part A: Does adding olomorasib to pembrolizumab, compared to placebo and pembrolizumab, prolong disease-free survival (DFS) in participants with pathologically confirmed resected stage II-IIIB NSCLC? (These participants had a KRAS G12C mutation, PD-L1 performance ranging from 0% to 100%, and had previously received chemotherapy.) Part B: Does adding olomorasib to durvalumab, compared to placebo and durvalumab, prolong disease-free survival (PFS) in participants with pathologically confirmed unresectable stage III non-small cell lung cancer? (These participants had a KRAS G12C mutation, had not experienced disease progression after concurrent platinum-based chemotherapy and radiation therapy, and had PD-L1 performance ranging from 0% to 100%.)

  • Test Drug

    Durvalumab Olomorasib PembrolizumabDurvalumab

Participate Sites
18Sites

Recruiting18Sites

2022-07-01 - 2030-01-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-05-31 - 2027-05-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-03-01 - 2026-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2025-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-01-29 - 2031-11-15

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2031-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-09-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB